Reduced risk of back pain following teriparatide treatment: a meta-analysis

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Osteoporosis International

• Publication date

  2006-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00198-005-2013-2PMID 16142502
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vertebral deformity, back symptoms, and functional limitations among older women: The Framingham Study

  2005cited by this paper
• The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis*

  2005cited by this paper
• Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.

  2005cited by this paper
• Vertebral compression fractures: manage aggressively to prevent sequelae.

  2003cited by this paper
• Hospital care of osteoporosis-related vertebral fractures

  2003cited by this paper
• The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis

  2003cited by this paper
• The hospital cost of vertebral fractures in the EU: estimates using national datasets

  2003cited by this paper
• A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.

  2002cited by this paper
• Mechanisms for the Enhancement of Fracture Healing in Rats Treated With Intermittent Low‐Dose Human Parathyroid Hormone (1–34)

  2002cited by this paper
• Osteoporosis--the disease of the 21st century?

  2002cited by this paper
• Treatment of Painful Osteoporotic Vertebral Fractures with Percutaneous Vertebroplasty or Kyphoplasty

  2001cited by this paper
• Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

  2001cited by this paper
• Initial Outcome and Efficacy of “Kyphoplasty” in the Treatment of Painful Osteoporotic Vertebral Compression Fractures

  2001cited by this paper
• Back Problems Among Postmenopausal Women Taking Estrogen Replacement Therapy: The Study of Osteoporotic Fractures

  2001cited by this paper
• The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study.

  2001cited by this paper
• Health‐Related Quality of Life in Postmenopausal Women With Low BMD With or Without Prevalent Vertebral Fractures

  2000cited by this paper
• A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

  2000cited by this paper
• Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group.

  2000cited by this paper
• Management of Patients with Vertebral Compression Fractures

  1999cited by this paper
• Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

  1999cited by this paper
• Intermittent Parathyroid Hormone (1–34) Treatment Increases Callus Formation and Mechanical Strength of Healing Rat Fractures

  1999cited by this paper
• Number and Type of Vertebral Deformities: Epidemiological Characteristics and Relation to Back Pain and Height Loss

  1999cited by this paper
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

  1999cited by this paper
• Effect of an Intermittent Weekly Dose of Human Parathyroid Hormone (1-34) on Osteoporosis: A Randomized Double-Masked Prospective Study Using Three Dose Levels

  1999cited by this paper
• Is Hormone Replacement Therapy a Risk Factor for Low Back Pain Among Postmenopausal Women?

  1998cited by this paper
• Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

  1998cited by this paper
• The Association of Radiographically Detected Vertebral Fractures with Back Pain and Function: A Prospective Study

  1998cited by this paper
• Health Impact Associated with Vertebral Deformities: Results from the European Vertebral Osteoporosis Study (EVOS)

  1998cited by this paper
• Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation

  1997influential reference
• Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

  1996cited by this paper
• The clinical impact of vertebral fractures: quality of life in women with osteoporosis.

  1996cited by this paper
• The worldwide problem of osteoporosis: insights afforded by epidemiology.

  1995influential reference
• Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

  1995cited by this paper
• Prevalence and incidence of vertebral deformities

  1993cited by this paper
• Association of osteoporotic vertebral compression fractures with impaired functional status.

  1993cited by this paper
• Incidence of clinically diagnosed vertebral fractures: A population‐based study in rochester, minnesota, 1985‐1989

  1992cited by this paper
• Contribution of vertebral deformities to chronic back pain and disability

  1992cited by this paper

• PTH induced osteoblast Slit3 to decrease aberrant sensory innervation in degenerated vertebral endplates to relieve low back pain in mice

  2026cites this paper
• Therapeutic effects of teriparatide on subchondral bone lesions and pain in mono-iodoacetate-induced osteoarthritis rat model

  2025cites this paper
• Bone Metabolic Changes and Osteoporosis During Pregnancy and Lactation: A View from Dental Medicine

  2025cites this paper
• Perioperative teriparatide for preventing proximal junctional kyphosis and failure in patients with osteoporosis after adult thoracolumbar spinal deformity surgery: a prospective randomized controlled trial

  2025cites this paper
• Multidisciplinary and Coordinated Management of Osteoporotic Vertebral Compression Fractures: Current State of the Art

  2024cites this paper
• Slit3 by PTH-Induced Osteoblast Secretion Repels Sensory Innervation in Spine Porous Endplates to Relieve Low Back Pain

  2024cites this paper
• Can Over Six Months of Teriparatide Treatment Prevent the Progression of Osteoporotic Thoracolumbar Compression Fracture?

  2024cites this paper
• Senescence of endplate osteoclasts induces sensory innervation and spinal pain

  2023cites this paper
• The efficacy of teriparatide (Cinnopar®) on bone repair in mandibular fractures: A single blinded randomized clinical trial.

  2023cites this paper
• Parathyroid hormone treatment partially reverses endplate remodeling and attenuates low back pain in animal models of spine degeneration

  2023cites this paper
• Pain Management in Osteoporosis

  2023cites this paper
• Management of Osteoporotic Vertebral Fracture: Review Update 2022

  2022cites this paper
• Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience

  2022cites this paper
• Quality of life of postmenopausal women with teriparatide, denosumab and alendronate: One-year prospective study with a propensity score-matched comparison

  2021cites this paper
• Assessment of the efficacy of teriparatide treatment for osteoporosis on lumbar fusion surgery outcomes: a systematic review and meta-analysis

  2020cites this paper
• Teriparatide relieves ovariectomy-induced hyperalgesia in rats, suggesting the involvement of functional regulation in primary sensory neurons by PTH-mediated signaling

  2020cites this paper
• The role of opioid analgesics in rheumatic disorders: a position paper from the Portuguese Rheumatology Society.

  2020cites this paper
• Prevention of bone loss and improvement of pain-related behavior in hind limb-unloaded mice by administration of teriparatide and bisphosphonate

  2020cites this paper
• Pharmacological study of teriparatide on ovariectomy-induced hyperalgesia in rats [an abstract of entire text]

  2020cites this paper
• Current Concepts in the Management of Osteoporotic Vertebral Fractures: A Narrative Review

  2020cites this paper
• CIA_A_224663 1693..1703

  2019cites this paper
• Teriparatide improves pain-related behavior and prevents bone loss in ovariectomized mice

  2019cites this paper
• The 2018 Guidelines for the diagnosis and treatment of osteoporosis in Greece

  2019cites this paper
• 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women

  2019cites this paper
• Decreased physical health-related quality of life—a persisting state for older women with clinical vertebral fracture

  2019cites this paper
• Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis.

  2019cites this paper
• Effect of teriparatide on quality of life in patients with postmenopausal osteoporosis: a retrospective cohort study

  2019cites this paper
• Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk

  2019cites this paper
• Postmenopausal Osteoporosis Treatment Update

  2018cites this paper
• Management for Osteoporotic Vertebral Fractures

  2018cites this paper
• Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)

  2018cites this paper
• Second Colombian Consensus on the Management of Post-menopausal Osteoporosis: 2017 update

  2018cites this paper
• II Consenso Colombiano para el Manejo de la Osteoporosis Posmenopáusica

  2018cites this paper
• What is the challenge? Up to 85% of patients with osteoporosis suffers from acute or chronic pain of different nociceptive and sometimes also neuropathic

  2018cites this paper
• Teriparatide rapidly improves pain-like behavior in ovariectomized mice in association with the downregulation of inflammatory cytokine expression

  2018cites this paper
• Gelenk- und Muskelschmerzen

  2018cites this paper
• Tratamiento de la osteoporosis: osteoporosis en la mujer premenopáusica y posmenopáusica. Osteoporosis en el varón

  2018cites this paper
• Understanding osteoporotic pain and its pharmacological treatment

  2018cites this paper
• Osteoporotic Thoracolumbar Fractures—How Are They Different?—Classification and Treatment Algorithm

  2017cites this paper
• Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis.

  2017cites this paper
• Management of chronic pain in osteoporosis: challenges and solutions

  2016cites this paper
• Clinical Management of Vertebral Compression Fractures.

  2016cites this paper
• Medical Treatment of Age Related Osteoporosis

  2016cites this paper
• Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)

  2016cites this paper
• Aggravation of spinal cord compromise following new osteoporotic vertebral compression fracture prevented by teriparatide in patients with surgical contraindications

  2016cites this paper
• Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report

  2016cites this paper
• Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis

  2016cites this paper
• Teriparatide Treatment in Elderly Patients With Sacral Insufficiency Fracture

  2016cites this paper
• Protocolo de diagnóstico y tratamiento de las fracturas vertebrales

  2016cites this paper
• Vertebral Fractures: Clinical Importance and Management.

  2016cites this paper
• Perioperative Medical Management of Spine Surgery Patients With Osteoporosis.

  2015cites this paper
• Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial

  2015cites this paper
• Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS)

  2015cites this paper
• Recommendations for preventing fracture in long-term care

  2015cites this paper
• Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study

  2015cites this paper
• Recommandations en vue de la prévention des fractures dans les établissements de soins de longue durée

  2015cites this paper
• Kyphoplasty Increases Vertebral Height, Decreases Both Pain Score and Opiate Requirements While Improving Functional Status

  2014cites this paper
• Progression of Hip Joint Deformity during the Management of Pelvic Insufficiency Fracture in a Patient with Rheumatoid Arthritis: A Case Report

  2014cites this paper
• Back pain in patients with severe osteoporosis on teriparatide or antiresorptives: a prospective observational study in a multiethnic population.

  2014cites this paper
• Fragility fractures requiring special consideration: vertebral fractures.

  2014cites this paper
• Best Practice & Research Clinical

  2014cites this paper
• Effects of teriparatide on lung function and pain relief in women with multiple osteoporotic vertebral compression fractures

  2014cites this paper
• Serum 25-hydroxyvitamin D level as an independent determinant of quality of life in osteoporosis with a high risk for fracture.

  2014cites this paper
• Preventive effects of conservative treatment with short-term teriparatide on the progression of vertebral body collapse after osteoporotic vertebral compression fracture

  2014cites this paper
• Risks and benefits of percutaneous vertebroplasty or kyphoplasty in the management of osteoporotic vertebral fractures

  2014cites this paper
• At Least One Cyclic Teriparatide Administration Can Be Helpful to Delay Initial Onset of a New Osteoporotic Vertebral Compression Fracture

  2014cites this paper
• The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong.

  2013cites this paper
• Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study

  2013cites this paper
• Comparison of the Therapeutic Effect of Teriparatide With That of Combined Vertebroplasty With Antiresorptive Agents for the Treatment of New-onset Adjacent Vertebral Compression Fracture After Percutaneous Vertebroplasty

  2013cites this paper
• Teriparatide Treatment of Severe Osteoporosis Reduces the Risk of Vertebral Fractures Compared with Standard Care in Routine Clinical Practice

  2013cites this paper
• Osteoporosis and fragility fractures: Vertebral fractures.

  2013cites this paper
• Vertebral compression fractures: a review of current management and multimodal therapy

  2013cites this paper
• Forsteo Observational Study ( EFOS ) 18-month follow-up of Greek women completing teriparatide treatment for osteoporosis

  2012cites this paper
• The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures

  2012cites this paper
• Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide: a meta-analysis

  2012cites this paper
• Reliability and validity of the Turkish version of the mini Osteoporosis Quality of Life Questionnaire

  2012cites this paper
• Conservative management of patients with an osteoporotic vertebral fracture: a review of the literature.

  2012cites this paper
• Microsoft PowerPoint-Post-Menopausal Hormone Tx-DOPS-KEEPS-Update

  2012cites this paper
• Treatment of repeated and multiple new-onset osteoporotic vertebral compression fractures with teriparatide.

  2012cites this paper
• Use of Recombinant Human Parathyroid Hormone(1–84) in Patients with Postmenopausal Osteoporosis

  2012cites this paper
• Osteoporotic vertebral fractures: current concepts of conservative care.

  2012cites this paper
• Osteoanabolic therapy: a non-surgical option of treatment for Kümmell’s disease?

  2012cites this paper
• Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain--the PROPOSE study.

  2011cites this paper
• [Novelties in pathophysiology, radiology diagnostics and conservative treatment of painful spine conditions and deformities].

  2011cites this paper
• Postmenopausal women with osteoporosis: experience when treated with teriparatide in clinical practice

  2011cites this paper
• Parathyroid hormone analogues in the treatment of osteoporosis

  2011cites this paper
• Once‐yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial

  2011cites this paper
• Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study

  2011cites this paper
• Teriparatide vs. Alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life

  2011cites this paper
• Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty

  2011cites this paper
• PTH analogues and osteoporotic fractures

  2010cites this paper
• Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS

  2010cites this paper
• Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)

  2010cites this paper
• Role of teriparatide in treatment of glucocorticoid-induced osteoporosis

  2010cites this paper
• Biologicals in Osteoporosis: Teriparatide and Parathyroid Hormone in Women and Men

  2010cites this paper
• Orthopedic Uses of Teriparatide

  2010influential citation
• Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases.

  2010cites this paper
• What are the beliefs, attitudes and practices of front-line staff in long-term care (LTC) facilities related to osteoporosis awareness, management and fracture prevention?

  2010cites this paper
• Effects of bone mineral density of the lumbar spine and prevalent vertebral fractures on the risk of immobility

  2010cites this paper
• Recombinant parathormone and osteoporosis: a review article

  2010cites this paper